Capsule

Rising Demand for Vegan Products and Growing Vegan Population to Drive Vegan Collagen Market at a CAGR of 9.1% through 2034

Retrieved on: 
Thursday, January 11, 2024
Powder, Capsule, Traction, Food, Health, Malnutrition, Cosmetics, Functional food, Drink, FMI, Pet industry

NEWARK, Del., Jan. 11, 2024 /PRNewswire/ -- According to Future Market Insights (FMI) analysis, the Global Vegan Collagen Market is expected to reach US$ 150.1 million in 2024. The market is projected to expand at a CAGR of 9.1%, reaching US$ 357.7 million by 2034. 

Key Points: 
  • NEWARK, Del., Jan. 11, 2024 /PRNewswire/ -- According to Future Market Insights (FMI) analysis, the Global Vegan Collagen Market is expected to reach US$ 150.1 million in 2024.
  • Request Exclusive Sample Report: Vegan Collagen Market Strategic Insights, https://www.futuremarketinsights.com/reports/sample/rep-gb-18794
    A primary driver of the vegan collagen market is the growing inclination of consumers toward functional and naturally produced components.
  • Vegan collagen products are becoming popular as consumers seek plant-based collagen substitutes rather than animal collagen.
  • Developing several forms of vegan collagen and growing awareness & adoption of vegan and cruelty-free lifestyles are set to further fuel the market."

Waxhead Sun Defense, Cymbiotika, Human Improvement, and Eat Drumroll Are Winners for Most Innovative New Products 2024

Retrieved on: 
Wednesday, January 10, 2024
Capsule, Zinc oxide, Health, Coconut oil, Science, Skin, Human, Fats, Safety, Longevity, GM, Dietary fiber

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- These four companies are uncompromising in upholding high standards of health and safety while raising the bar on satisfaction and peak experience. [See full press release.]

Key Points: 
  • Waxhead Sun Defense, Cymbiotika, Human Improvement, and Eat Drumroll are the ones to watch.
  • Co-founders Kari and Shannon Kenner established Waxhead Sun Defense™ to provide responsible skin protection for outdoor enjoyment in the sun.
  • Human Improvement™ : Its name is its mission: "Using innovative ingredients, we make clean, functional products that are formulated to actually help humans improve."
  • Eat Drumroll® satisfies without the "empty calories" of refined grains and sugar, and without trans fats and saturated fats.

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Medical Subject Headings, Diarrhea, Marketing, Platinum, INN, Peritoneum, Constipation, Fatigue, Woman, Ovarian cancer, ATC, Insomnia, Hypertension, Capsule, International, Cough, Tubing (recreation), Weakness, Headache, Disease, Nausea, Neutropenia, Language, DNA, Mouth, Cancer, Neoplasm, Thrombocytopenia, Abdomen, Dizziness, Platelet, PARP, Neutrophil, Appetite, European Medicines Agency, Back pain, Uterus, Enzyme, Select, Cell, Patient, Time, Safety, Anatomy, Anemia, Arthralgia, Vomiting, IIA, Periodic breathing

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Halo Appliances Set to Launch Revolutionary Halo Capsule X Cordless Vacuum Cleaner in the United States

Retrieved on: 
Monday, January 8, 2024
The Capsule, Inorganic polymer, Capsule, BOCA, Longevity, Vacuum

BOCA RATON, Fla., Jan. 8, 2024 /PRNewswire/ -- Halo Appliances is excited to announce the U.S. launch of the Halo Capsule X, an innovative cordless vacuum cleaner.

Key Points: 
  • BOCA RATON, Fla., Jan. 8, 2024 /PRNewswire/ -- Halo Appliances is excited to announce the U.S. launch of the Halo Capsule X, an innovative cordless vacuum cleaner.
  • With over 25 years in the vacuum cleaner industry, Bagwell identified key issues in existing cordless vacuums: short run times, poor performance, and inadequate capacities.
  • The Halo Capsule X is his response, designed to effortlessly meet consumer needs.
  • "Introducing the Halo Capsule X to the U.S. is a major step in revolutionizing home cleaning.

Calliditas Therapeutics appoints Maria Törnsén as President North America

Retrieved on: 
Sunday, January 7, 2024
NOX, Immunoglobulin A, Risk, FDA, Sustainability, Capsule, Person, Sarepta Therapeutics, Therapy, IgA nephropathy, Growth, SVP, Patient, CALT, Pharmaceutical industry

STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.

Key Points: 
  • STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.
  • Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles.
  • Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics.
  • "We are pleased to welcome Ms Törnsén to the executive management team as President of our US operations.

Calliditas Therapeutics appoints Maria Törnsén as President North America

Retrieved on: 
Sunday, January 7, 2024
NOX, Immunoglobulin A, Risk, FDA, Sustainability, Capsule, Person, Sarepta Therapeutics, Therapy, IgA nephropathy, Growth, SVP, Patient, CALT, Pharmaceutical industry

STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.

Key Points: 
  • STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.
  • Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles.
  • Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics.
  • "We are pleased to welcome Ms Törnsén to the executive management team as President of our US operations.

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

Retrieved on: 
Friday, January 5, 2024
Marketing, National Rosacea Society, Entrepreneurship, Food, CEA, Minocycline, Rosacea, FDA, Capsule, NDA, Red, New Drug Application, Face, Patient, Food and Drug Administration, Erythema, Pharmaceutical industry

SCOTTSDALE, Ariz., Jan. 05, 2024 (GLOBE NEWSWIRE) --  Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company has submitted a New Drug Application (“NDA”) to the FDA seeking approval for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. DFD-29 is being developed in collaboration with Dr. Reddy’s Laboratories Ltd.

Key Points: 
  • DFD-29 is being developed in collaboration with Dr. Reddy’s Laboratories Ltd.
    “This NDA submission is a significant milestone for Journey Medical and we look forward to collaborating with the FDA during its review to bring DFD-29, a potentially differentiated, best-in-class oral rosacea treatment, one step closer to patients.
  • The NDA submission is supported by positive data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea.
  • The Phase 3 clinical trials achieved all co-primary and secondary endpoints, and subjects completed the 16-week treatment with no significant safety issues.
  • DFD-29 has the potential to become the only oral, systemic therapy to address both inflammatory lesions and erythema (redness) from rosacea, as demonstrated in the clinical trials.

Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 16, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Medical Subject Headings, Marketing, European Commission, Agency, Neuropathic pain, INN, Risk, ATC, Capsule, International, European, Spinal cord, Language, Butyric acid, Brain, Anxiety disorder, Anxiety, GAD, Nervous, Peripheral neuropathy, Zentiva, Select, Committee, Patient, Risk management, Anatomy, Medicine, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 16, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Pregabalin Zentiva, pregabalin, Date of authorisation: 17/07/2015, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Marketing, Hypothyroidism, INN, Woman, Progression-free survival, Nausea, Syndrome, Heart, Cancer, Inflammation, Skull, Proteinuria, Anatomy, Cell division, IIA, Diarrhea, Fatigue, ATC, Capsule, Bleeding, Pancreas, RET, VEGF, FGFR, Cerebral edema, Neoplasm, Stroke, Enzyme, Liver failure, Safety, Kidney cancer, Arthralgia, Heart failure, Patient, Urine, Medical Subject Headings, Stomatitis, Immune system, Everolimus, International, Encephalopathy, Language, Somatic symptom disorder, Blood, Mouth, Catherine Disher, Select, Medicine, Vomiting, Pembrolizumab, Cholesterol, PDGF, Kidney failure, Weight loss, Headache, KIT, Brain, Acral lentiginous melanoma, Swelling, Hypoesthesia, Splenic infarction, Confusion, European Medicines Agency, RCC, Kidney, Growth, Sunitinib, Hypercholesterolemia, Rash, Medical device

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Urine, Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Immune system, Stomach, Multiple sclerosis, ATC, Pain, Capsule, International, Spinal cord, Disease, PML, Nausea, Language, Brain, Mouth, Eye, Inflammation, Flushing, Antioxidant, European Medicines Agency, Gene, Glatiramer acetate, Select, Central nervous system, Patient, Cell, Safety, Encephalitis, Anatomy, IIA, Optic nerve, Skin, Medical device

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised